Recursion Pharmaceuticals Inc (RXRX)
9.995
-0.06
(-0.55%)
USD |
NASDAQ |
May 15, 16:00
9.95
-0.04
(-0.45%)
After-Hours: 16:09
Recursion Pharmaceuticals Cash from Financing (TTM): 152.11M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 152.11M |
December 31, 2023 | 140.13M |
September 30, 2023 | 206.73M |
June 30, 2023 | 155.30M |
March 31, 2023 | 154.18M |
December 31, 2022 | 154.34M |
September 30, 2022 | 10.88M |
Date | Value |
---|---|
June 30, 2022 | -2.547M |
March 31, 2022 | 458.49M |
December 31, 2021 | 458.54M |
September 30, 2021 | 464.78M |
June 30, 2021 | 705.60M |
March 31, 2021 | 242.27M |
December 31, 2020 | 246.14M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-2.547M
Minimum
Jun 2022
705.60M
Maximum
Jun 2021
253.35M
Average
181.02M
Median
Cash from Financing (TTM) Benchmarks
Eli Lilly and Co | 2.772B |
Absci Corp | -4.483M |
Palatin Technologies Inc | 5.553M |
Oragenics Inc | 0.2839M |
Actinium Pharmaceuticals Inc | 28.87M |